Mydayis™ (mixed salts of a single-entity amphetamine product) – New drug approval
June 20, 2017 – Shire announced the FDA approval of Mydayis (mixed salts of a single-entity amphetamine product) extended-release capsules for the treatment of attention deficit hyperactivity disorder (ADHD) in patients 13 years and older.
Top